ArticleComputational and structural biotechnology journal2026
Association between Urinary-Extracellular-Vesicle-Enriched Proteome Dynamics and Oncological Outcomes Following Concurrent Chemoradiation in Locally Advanced Cervical Cancer.
Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although concurrent chemoradiation (CCRT) is the standard of care for locally advanced cervical cancer, oncological outcomes remain suboptimal. Noninvasive monitoring of treatment responses could improve therapeutic management. This study investigated the temporal dynamics of extracellular vesicle (EV)-enriched urinary proteomes in patients with locally advanced cervical cancer undergoing CCRT to identify physiobiological shifts and proteins associated with treatment response and survival. Urine samples from 42 patients were collected longitudinally before, 1 month post-, and 3 months post-CCRT completion (126 samples). Urinary EVs were enriched using strong-anion-exchange magnetic beads. Proteomic profiling was performed using liquid chromatography-tandem mass spectrometry. Differential protein abundance and time-varying Cox regression analyses were used to correlate the proteomic signatures with CCRT response and overall survival. Analysis of longitudinal samples yielded 2,352 quantifiable proteins. Of these, 1,055 exhibited significant temporal shifts. Pathway analysis revealed that tumors and virus-associated proteins peaked at 3 months posttreatment, corresponding to the clinical response assessment window. By 3 months, nonresponders exhibited pronounced suppression of adaptive immune pathways and up-regulation of protein homeostasis and degradation pathways. Time-varying survival analysis identified 8 proteins driven by an altered T-complex ring complex/chaperonin containing T-complex protein 1, ribosomal proteins, and immune-related proteins associated with overall survival. Six of these were expressed in cervical tumor tissues based on the Human Protein Atlas. Overall, EV-enriched urinary proteomics provides a noninvasive liquid biopsy method for monitoring biological dynamics during CCRT. The observed immune suppression in nonresponders and the 8-protein prognostic signature offer preliminary insight into survival patterns and could help guide future studies on adjuvant immune-enhancing approaches.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.